Clinical trials: Neoplasms, Germ Cell and Embryonal
Chordoma
Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma
This phase I trial studies the side effects of nivolumab with or without stereotactic radiosurgery (SRS) in treating patients with chordoma that has come back or spread from where it started to other places in the body.
- Trial name
- NCT02989636
- Testing
- Laboratory Biomarker Analysis, Nivolumab, Stereotactic Radiosurgery
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Malignant Melanoma
Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma
High-dose IL-2 treatment for metastatic melanoma has been approved by the FDA in 1998. Studies of GM-CSF plus IL-2 have not addressed the approved dose and schedule.
- Trial name
- NCT00616564
- Testing
- GM-CSF
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Mt. Sinai Medical Center, Miami
Melanoma, NSCLC
A Study of BCD-135 in Patients With Advanced Solid Tumors
A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-135 (JSC BIOCAD, Russia) in Patients with Advanced Solid Tumors
- Conditions
- Melanoma, NSCLC, Renal Cell Carcinoma, Bladder Cancer
- Trial name
- NCT03464032
- Testing
- BCD-135
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Biocad
Neuroendocrine Tumor, Carcinoid Tumor
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
The purpose of this research study is to determine the safety of the combination of SOM230 and RAD001, as well as determine the highest dose of this combination that can be given to people safely.
- Conditions
- Neuroendocrine Tumor, Carcinoid Tumor, Pancreatic Neuroendocrine Tumor
- Trial name
- NCT00804336
- Testing
- SOM230, RAD001
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Dana-Farber Cancer Institute
Synovial Sarcoma, Soft Tissue Sarcoma
A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors
This is an open-label, non-randomized, first-in-human Phase 1/2 study designed to evaluate the safety and tolerability of CFT8634 in subjects with synovial sarcoma and SMARCB1-null tumors who: have received prior systemic…
- Trial name
- NCT05355753
- Testing
- CFT8634
- Where
- 12 sites in United States
- Volunteers
- 49 people
- Sponsor
- C4 Therapeutics, Inc.
Glioblastoma Multiforme
Sonodynamic Therapy With ExAblate System in Glioblastoma Patients
The goal of this prospective, non-randomized, single-arm study is to evaluate the safety and feasibility of sonodynamic therapy with 5-aminolevulinic acid in patients with newly diagnosed cerebral glioblastomas using the ExAblate…
- Trial name
- Sonic ALA (NCT04845919)
- Testing
- 5-Aminolevulinic Acid
- Where
- Italy
- Volunteers
- 5 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Gliomas
C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression
This study will investigate how well Carbon Acetate PET/CT imaging helps to correctly identify recurrent tumor versus post treatment effects (radionecrosis) in patients with previously treated high grade brain gliomas.
- Trial name
- NCT01961934
- Testing
- Sodium Acetate C11 PET/CT Imaging
- Where
- United States
- Sponsor
- Phoenix Molecular Imaging
Testicular Neoplasms, Neoplasms, Germ Cell and Embryonal
Avelumab in Refractory Testicular Germ Cell Cancer.
This is a proof-of-concept study to define efficacy of AVELUMAB in patients with multiple relapsed/refractory germ cell tumors (GCTs).
- Conditions
- Testicular Neoplasms, Neoplasms, Germ Cell and Embryonal, Neoplasms, Testicular Diseases
- Trial name
- NCT03403777
- Testing
- Avelumab
- Where
- Slovakia
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute, Slovakia
Glioma
MRS of Glioma Genomics
In France, about 5000 new people with a primary malignant brain tumor are diagnosed each year. The most common primary tumors are gliomas, originating from glial cells (astrocytomas and oligodendrogliomas).
- Trial name
- GLIOMRS (NCT05700071)
- Testing
- MRI
- Where
- 2 sites in France
- Volunteers
- 110 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Epithelial Tumor, Malignant, Neuroendocrine Tumors
Proton Boost for Locally Advanced HEAD AND NECK TUMORS
The aim of this research project is to test the local response and the acute toxicity (which can be observed within 90 days).
- Trial name
- NCT03183271
- Testing
- external beam proton radiation therapy.
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- CNAO National Center of Oncological Hadrontherapy
Retinoblastoma, Secondary Primary Malignancies After Retinoblastoma
New Strategies to Detect Cancers in Carriers of Mutations in RB1
Rationale: Individuals with a cancer predisposition due to a mutation in the paradigm tumor suppressor gene RB1, have a high risk to develop the childhood cancer retinoblastoma (Rb).
- Trial name
- NIRBTEST (NCT04164134)
- Testing
- blood draw
- Where
- 3 sites in France, Germany and 1 more
- Volunteers
- 378 people, healthy volunteers welcome
- Sponsor
- Amsterdam UMC, location VUmc
Glioblastoma Multiforme
mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme
The standard or usual treatment for this disease is standard chemotherapy alone. AZD2014 is a new type of drug for glioblastoma multiforme. In the laboratory it has been shown to slow the growth of glioblastoma multiforme.
- Trial name
- NCT02619864
- Testing
- AZD2014
- Where
- 4 sites in Canada
- Volunteers
- 15 people
- Sponsor
- Canadian Cancer Trials Group
Neuroblastoma
SF1126 for Patients With Relapsed or Refractory Neuroblastoma
SF1126 is a novel inhibitor of PI3 kinase and mTOR that includes an active moiety (consisting of LY294002) linked to an RGDS tetrapeptide that targets the active agent to integrin expressing tissues.
- Trial name
- NCT02337309
- Testing
- SF1126
- Where
- 11 sites in United States
- Volunteers
- 4 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Glioblastoma Multiforme (GBM), Glioblastoma
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
The purpose of this study is to evaluate the safety and efficacy of administering the medication capecitabine along with temozolomide when you start your monthly regimen of oral temozolomide for the treatment of your newly…
- Conditions
- Glioblastoma Multiforme (GBM), Glioblastoma, Glioma of Brain, Glioblastoma, Adult
- Trial name
- CAPTEM (NCT03213002)
- Testing
- Capecitabine, Temozolomide
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Northwell Health
Metastatic Malignant Melanoma
A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma
The primary objective of this study is to determine the progression-free survival (PFS) of participants with previously untreated metastatic malignant melanoma when treated with IMC-1121B (ramucirumab) alone or in combination…
- Trial name
- NCT00533702
- Testing
- IMC-1121B (ramucirumab), Dacarbazine
- Where
- 17 sites in United States
- Volunteers
- 106 people
- Sponsor
- Eli Lilly and Company
Brain and Central Nervous System Tumors
Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and combining chemotherapy with autologous bone marrow transplantation or…
- Trial name
- NCT00003101
- Testing
- filgrastim, busulfan, lomustine
- Where
- 7 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pediatric Cancer
TEMOkids Study : A Phase I Pediatric Study for KIMOZO, Oral Suspension of Temozolomide
Non-randomized, international, multi-centre, open-label, single arm study to determine the pharmacokinetic (PK) parameters of a single dose of an oral suspension of temozolomide (KIMOZO) in the pediatric population aged 1 year…
- Trial name
- NCT04610736
- Testing
- Temozolomide Oral Suspension
- Where
- 11 sites in France, Germany and 3 more
- Volunteers
- 49 people
- Sponsor
- Orphelia Pharma
Glioblastoma (GBM)
Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening: Advanced Brain Tumor TheRApy Clinical Trial In Patients Scheduled for shOrt Course radiatioN
Patients will receive in addition to standard histology analysis also the PDC- based drug screening.
- Trial name
- ATTRACTION (NCT07627334)
- Testing
- CBmed drug screening platform
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Medical University of Vienna
Chordoma, Chemotherapy Effect
Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma
This phase II trial studies how well Camrelizumab combined with Apatinib work in treating participants with chordoma that has spread to other places in the body, which may interfere with the ability of tumor cells to grow and…
- Trial name
- NCT06140732
- Testing
- camrelizumab and apatinib
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Xuanwu Hospital, Beijing
Ganglioneuroblastoma, Recurrent Neuroblastoma
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
This randomized phase II trial studies how well irinotecan hydrochloride and temozolomide with temsirolimus or dinutuximab work in treating younger patients with neuroblastoma that has returned or does not respond to treatment.
- Trial name
- NCT01767194
- Testing
- Dinutuximab, Irinotecan Hydrochloride, Laboratory Biomarker Analysis
- Where
- 157 sites in United States, Australia and 3 more
- Volunteers
- 73 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.